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Abstract 
Heparin is an important anticoagulant drug, about one billion doses are produced annually. It 
is a polydisperse sulfated polysaccharide, and the inherent heterogeneity makes the analysis 
of heparin difficult. The global crisis resulting from adulterated heparin in 2008 has drawn 
renewed attention to the challenges that are associated with the quality control  and 
characterization of this complex biological medicine from natural sources. The present study 
addresses the need for simple and user-friendly analytical methods for the fast and accurate 
quantification of heparin in complex matrices. Direct quantification of heparin in the low 
microgram per mL range was accomplished using a specific commercially available assay 
based on the fluorescent molecular probe Heparin Red, simply by mixing the heparin 
containing sample and a reagent solution in a 96-well microplate followed by fluorescence 
readout. A screening of typical impurities in raw heparin (selected other glycosaminoglycans, 
residual nucleic acids and proteins), related to the extraction from animal tissues, as well as 
of components of the urine matrix (inorganic salts, amino acids, trace proteins) revealed that 
these compounds even in large excess have no or very little effect on the accuracy of 
heparin determination. Heparin spike detection in urine, a biological  multicomponent matrix, 
also showed good accuracy. We envision applications of this mix-and-read assay in the 
process and quality control in heparin manufacturing, but also in pharmacokinetic studies as 
a convenient tool for measuring of the urinary excretion of heparins.   
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Introduction 
Heparins are widely used clinical anticoagulants [1, 2], about one billion doses are produced 
each year.[3]  Heparin is a polydisperse mixture of sulfated  linear polysaccharides that 
consist  of disaccharide repeating units (scheme 1, left) and have a high negative charge 
density of about -1.7 per monosaccharide. Unfractionated heparin (UFH, mean molecular 
weight between 13000 and 15000), is clinically applied since the 1930s. In recent decades, 
there has been a trend towards use of low molecular weight heparins (LMWH, mean 
molecular weight between 4000 and 7000). The latter are prepared from UFH by partial 
depolymerisation and display more favourable pharmacokinetics and lower side effects. In 
the following, the term “heparin” refers to unfractionated heparin.  
Heparin is prepared by extraction from the tissues of slaughterhouse animals, mainly porcine 
intestine. The process involves protein hydrolysis at alkaline pH in the presence of proteases 
and enrichment of the heparin like GAGs by anion exchange resin.[4] The raw or crude 
heparin obtained at this stage is typically a mixture of many components – a rough estimate 
is 50% heparin and 50% other compounds [5], mostly other glycosaminoglycans of lower 
sulfation degree (such as dermatan sulfate and chondroitin sulfate) but also residual 
biomaterials including proteins, peptides, nucleic acids, and lipids.  Preparation of raw 
heparin is typically performed outside of GMP (Good Manufacturing Practices). There is a 
significant process-dependent  variation in the composition of raw heparin. The crude 
material is then converted under GMP conditions to pharmaceutical grade heparin in a 
further multistep purification process, involving precipitation, ion exchange chromatography 
and chemical treatment. Monitoring the raw heparin preparation and purification process is 
challenging, and new, effective analytical methods for fast in-process quantification of 
heparin have the potential to improve production efficiency and reduce waste.[6]  
In 2008, the economically motivated adulteration of raw heparin with oversulfated chondroitin 
sulfate, a substance that mimics the anticoagulant activity of heparin but is much cheaper to 
produce, was associated with about 200 deaths and hundreds of adverse advents worldwide. 
This “heparin crisis” has drawn renewed attention to the challenges that are associated with 
the characterization, quality control and standardisation of complex biological medicines from 
natural sources.[7] The tragic event resulted in the introduction of advanced analytical 
screening of pharmaceutical heparin, including NMR spectroscopy, capillary electrophoresis , 
and HPLC.  To ensure continued safety of heparin, the US Food and drug administration 
(FDA) recommended continued development of additional methods for the quality control of 
heparin.  
 
 
In clinical settings, heparin blood levels are monitored by the antithrombin-mediated effect on 
the clotting cascade or individual coagulation factors. These assays can, however, not be 
readily transferred to other complex matrices. Rather, heparin quantification in urine, for 
example, is achieved by challenging and time consuming protocols that either involve 
radiolabeling [8, 9] or require the isolation of heparin from urine and staining/colorimetric 
procedures, eventually including electrophoresis [10, 11]. Depending on the methodology, 
urinary recovery of heparin between 1% and 39 weight % of injected doses has been 
reported. In one study [10], roughly one half of the excreted was characterized as unchanged 
heparin, and the other half as a partially desulfated metabolite with a charge density of about 
-1.5 per monosaccharide. There is a renewed recent interest in non-invasive (in particular 
oral)  delivery options for heparin [12, 13], and quantifying urinary excretion is part of the 
pharmacokinetic analysis.[14] Oral uptake of a 1000 U/kg body weight heparin dose resulted 
in urinary concentrations between 0,2 and 4 µg/mL. [14]    
There is a need for simple and user-friendly analytical methods for fast and accurate 
quantification of heparin in complex matrices. Such methods would be of great value for 
process control in crude heparin preparation and purification, assessing the comparibility of 
raw heparin batches in terms of heparin content, and for heparin quantification in complex 
biological matrices other than blood samples. A key requirement on such an assay is 
elimination of matrix effects by suppressing the potential  interference of a multitude of 
abundant matrix components.  Cationic dyes, such as Alcian Blue and Azure A have 
historically been used to detect heparin colorimetrically, but it is well known that many other 
substances interfere with the non-covalent binding that underpins these assays.[15] 
 
                   
Scheme 1. Major repeating disaccharide unit of heparin (left). Structure of the polycationic 
fluorescent probe Heparin Red (left).   
 
We describe here the application to heparin detection in various matrices of the fluorescent 
probe “Heparin Red”, initially described as an experimental probe for heparin detection [16] 
and meanwhile developed further into commercially available assays. Heparin Red is a 
polyamine derivative of a red-emissive perylene diimide fluorophore (scheme 1, right). It 
forms a supramolecular complex with the target, with aggregation of the probe molecules at 
 
the heparin template and contact quenching of fluorescence (scheme 2). The strong binding 
of the polycationic probe to polyanionic heparin appears to be controlled by both electrostatic 
and aromatic pi-stacking interactions [17]. 
 
Scheme 2. Schematic representation of fluorescence quenching of the molecular probe Heparin Red 
in the presence of polyanionic heparin.     
 
We have recently applied the commercial Heparin Red Kit, optimized for blood plasma 
matrix, to the direct quantification of heparins (including unfractionated heparin, low 
molecular weight heparin and non-anticoagulant heparins) and fucoidan (a polysulfated 
polysaccharide from brown algae)  in human plasma.[18, 19] The Kit is of particulat value for 
non-anticoagulant heparins that can not be analyzed by standard coagulation assays and is 
emerging as a tool for pharmacokinetic analysis of this promising class of drug 
candidates.[20] While the Heparin Red Kit provides convincing results in the highly complex 
plasma matrix, it is prone to interference by nucleic acids (ususally not present in blood 
plamsa at signicant concentrations) and does not give satisfactory results for heparin 
detection in urine. 
In this contribution, we describe for the first time the application of Heparin Red Ultra, a more 
recently released commercial assay, to heparin quantification in various matrices including 
urine. Heparin Red Ultra has a different reagent formulation and is provided as a ready-to-
use solution that simply needs to be mixed with the heparin containing sample. The study 
includes a systematic screening of the effect of individual components of raw heparin 
preparations and of the urine matrix on the accuracy of the assay.    
 
 
 
 
 
 
Materials and Methods 
Instrumentation 
Fluorescence measurements 
Fluorescence was measured with a microplate reader Biotek Synergy Mx (Biotek  
Instruments, Winooski, VT, USA), excitation at 570 nm, emission recorded at 605 nm,  
spectral band width 17 nm, gain 110, read height of 8 mm. 
 
Microplates 
For fluorescence measurements 96 well microplates, polystyrene,  Item No 655076, were 
purchased from Greiner Bio-One GmbH, Frickenhausen.  
 
Pipettes  
Transferpette® 0,5-10µl, Transferpette®-8 20-200µl and Transferpette®-12 20-200µl, 
purchased from Brand GmbH, Wertheim. Rainin Pipettes 100-1000µl, 20-200µl, and 2-20µl 
purchased from Mettler Toledo, OH, USA.  
 
 
Reagents 
 
Heparin Red® Ultra was a gift from Redprobes UG, Münster, Germany. Product No 
HRU001, Lot 003.   
Aqueous solutions were prepared with HPLC grade water purchased from VWR, product No 
23595.328. Unfractionated heparin sodium salt from porcine intestine mucosa was 
purchased from Sigma-Aldrich GmbH, Steinheim, product number H5515, Lot SLBK0235V. 
Heparin stock solutions were stored at 4-8°C. Inorganic salts were >99% pure. Chondroitin 
sulfate A sodium salt from bovine trachea, product number C9819, Lot SLBQ0017V, 85% 
pure according to 13C NMR spectrum (Certificate of analysis); Dermatan sulfate sodium salt 
from porcine intestinal mucosa, 100% pure according to 13C NMR spectrum (Certificate of 
analysis), product number C3788, Lot SLBM9912V; DNA sodium salt from salmon testes, 
product number D1626, Lot SLBF9870V; RNA from yeast, product number 10109223001 
Roche, Lot 13833221; Glycine, product number G5417, Lot CDBC1274V;  Immunogloblin G 
(IgG) from human serum, product number I4506, Lot SLBK8678V, 97% pure according to 
SDS electrophoresis (Certificate of analysis); “Protease” isolated from Streptomyces griseus, 
lyophilized powder, caseinolytic activity >3.5 units/mg, mixture of several proteinolytic 
activities (serin type proteases including trypsin, zinc endopeptidase, zinc aminopeptidase, 
zinc carboxypeptidase), product number P5147, Lot SLBQ0332V; Human serum albumin, 
 
product number A1653, Lot SLBD1834V, 99% pure according to agarose electrophoresis 
(Certificate of analysis); and Tris(2-carboxyethyl)phosphine (TCEP), product number 646547, 
Lot MKBZ1912V, as 0.5 M solution, pH 7.0 adjusted with ammonium hydroxide, were all 
purchased from Sigma Aldrich GmbH, Steinheim, Germany. 
 
Urine 
Urine samples were collected from two voluntary healthy donors, stored at -20°C and thawed 
before use. Heparin spiked urine samples were either used directly after spiking, or stored at 
-20°C and thawed prior to use. 
   . 
 
Assays 
 
Heparin Red® Ultra 
For determination of heparin concentrations in aqueous or urine samples, the protocol of the 
provider for a 96-well microplate assay was followed. In brief, 5 µL of the heparin spiked 
sample was pipetted into a microplate well. Then, 180 µL of Heparin Red Ultra solution was 
added to the samples as simultaneously as possible. For samples numbers > 10, a 12-
channel pipette was used for addititon of Heparin Red Ultra solution. The microplate was 
immediately introduced in the fluorescence reader and mixing was performed using the plate 
shaking function of the microplate reader (setting “high”, 1 minute). Immediately after mixing, 
fluorescence was recorded within 1 minute. Detections in water and urine were performed as 
either duplicates  or triplicates. 
 
HemoCue® albumin 201 system 
The Hemocue albumin 201 system is a portable, lab-accurate system for quantification of  
human serum albumin in urine. For determination of albumin concentrations in µg/mL, the 
protocol of the provider was followed.  
 
 
 
 
 
 
 
 
 
 
Results and discussion 
Detection of heparin in complex matrices 
The Heparin Red Ultra assay was first applied to the detection of heparin at different 
concentrations in aqueous samples. Figure 1 shows the decrease of fluorescence signal with 
increasing heparin concentration. Response shows good linearity in the range 0-7 µg/mL.  
 
Figure 1. Normalized response curve of the Heparin Red Ultra fluorescence assay to aqueous heparin 
samples in the concentration range 0-10 µg/mL. Manually performed microplate assay. Excitation at 
570 nm, fluorescence emission at 605 nm. Averages of duplicate determinations; CV for the linear 
range 0 to ≈7 µg/mL (averaged over all concentrations): 1,7 %.  
Analytical precision was determined for selected heparin concentrations, CVs relating to 
fluorescence internsity were 0.3% for c(heparin) = 0 µg/mL (n=8) and 2.9 % for c(heparin) = 
4,38 µg/mL (n=8). At the latter concentration, an about 50% decrease of fluorescence 
intensity is observed. 
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It should be noted at this point that, as described previously for the Heparin Red Kit [19], the 
sensitivity of the assay is tunable by modification of the protocol. Increasing the sample 
volume from 5 µL (see “Materials and Methods”, “Assays”) to 10 µL  enhances the sensitivity 
about twofold, i.e. only 0.4 µg/mL heparin trigger a 10% fluorescence reduction (data not 
shown). Also, the low molecular weight heparin enoxaparin is in 10 µL samples detected with 
good sensitivity (about 50% fluorescence reduction by 5 µg/mL, data not shown). The gain in 
sensitivity might, however, be at the cost of accuracy of the assay in the presence of 
potentially interfering compounds (figure 2). 
To elicit the performance of the assay for heparin quantification in diverse matrices, we have 
repeated the assay at two heparin concentrations, 0 µg/mL (absence of heparin) and 4,38 
µg/mL (about 50% reduction of fluorescence signal) in the presence of individual substances 
that are potential components of crude heparin preparations or of the urine matrix. These 
substances include inorganic salts, other glycosaminoglycans, proteins, amino acids and 
nucleic acids.  
Results are shown in figure 2. The control sample (leftmost in the diagram) refers to water 
and 4,38 µg/mL heparin in water, respectively. Fluorescence in the presence of most of the 
added substances at specified concentrations is within a narrow range, as indicated by the 
grey horizontal bars, of ± 2.6 % (heparin free samples) or ± 3.1 % (heparin spiked samples) 
from control, means no or very little interference. We conclude that the Heparin Red Ultra 
assay suppresses a wide variety of potential interferences in complex matrices. 
In detail, the assay tolerates 150 mM NaCl, 75 mM KCl, and inorganic salts of di/trivalent 
ions (including Ca2+, Mg2+, sulfate and phosphate) in the 10-50 mg/mL range, nucleic acids 
(DNA, RNA) at 25-50 µg/mL, the glycosaminoglycans chondroitin sulfate an dermatan sulfate 
at 25 µg/mL, the amino acid glycine at 20 mM, immunoglubulin G (a major plasma protein, 
also present in urine in trace amounts) at 30 µg/mL, and a commercial protease preparation 
at 2 mg/mL (proteases are extensively used in the manufacture of crude heparin). Only 
human serum albumin (HSA), the most abundant plasma protein and potential trace protein 
in urine, strongly masks fluoresecence response to heparin in concentrations as low as 30 
µg/mL.  
  
Figure 2. Fluorescence response of the Heparin Red Ultra assay to a heparin-free aqueous sample 
(red bars) and a sample containing 4,38 µg/mL heparin (blue bars), in the presence various 
substances at specified concentrations. Control (leftmost bars) refers to water or 4,38 µg/mL heparin 
in water, respectively.  Averages of duplicate determinations with indicated error bars. IgG: 
Immunoglobuline G. HSA: Human serum albumin. 
Interference by human serum albumine was analyzed in more detail. The masking effect 
increases with increasing concentrations of the protein (figure 3). The interference by 20 
µg/mL HSA is completely eliminated by protease pretreatment of the heparin containing 
sample (commercial protease mix 1 mg/mL, 1 h at ambient temperature; data not shown), 
suggesting that only the intact HSA is masking heparin detection. 
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Figure 3. Fluorescence response of the Heparin Red Ultra assay to a heparin-free aqueous sample 
(red bars) and a sample containing 4,38 µg/mL heparin (blue bars), in the presence of human serum 
albumin (HSA) in varying concentrations.. Control (rightmost bars, or c(HSA) = 0 µg/mL) refers to 
water or 4,38 µg/mL heparin in water, respectively.  Averages of duplicate determinations; CV 
averaged over all concentrations: 0.5 %.  
 
Our hypothesis about the mechanism of HSA interference is based on protonation of 
carboxylate side chains (of Glu and Asp)  in HSA in the acidic reaction medium provided by 
the Heparin Red Ultra assay. While the detailed composition of the reagent solution is not 
given by the provider, we have measured a pH value of 3.0 in a 1:1 mixture of Heparin Red 
Ultra solution and water with a standard glass electrode. At such a low pH value, the 
carboxylate side chains of Glu and Asp are expected to become protonated. Along with this, 
the 585 amino acid protein HSA would be converted from a charge-balanced zwitterionic 
species into polycationic polymer having an overall charge of +99 (due to the cationic 
residues of Lys, Arg and His).[21] This polycationic polymer may compete with the Heparin 
Red molecule for heparin binding and thus suppress the fluorescence response. It is not 
obvious, however, why only HSA should exhibit competitive heparin binding at low 
concentration but not immunoglobulin G or the protease (figure 2).    
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We therefore speculated that a specific structural feature of HSA triggers its strong masking 
effect. An unusual feature of HSA is the presence of 17 intramolecular disulfide bonds 
between Cys thiol residues.[21] This creates a number of intramolecular loops within the 
polypeptide chain in which the cationic amino acid residues are preorganized, possibly 
leading to a strong binding of the polyanionic heparin molecules. To support this idea, we 
incubated the HSA containing samples with the disulfide cleaving agent tris(2-
carboxyethyl)phosphine (TCEP), 25 mM at ambient temperature for 15 minutes.[22] While 
TCEP itself does not effect the response of Heparin Red Ultra to heparin, it is able to 
eliminate the masking effect of HSA (figure 4). Since TCEP is commercially available in form 
of a “ready-to-use” solution, we found at the same time a very convenient sample pre-
treatment method to overcome HSA interference in heparin detection by Heparin Red Ultra.    
  
Figure 4. Fluorescence response of the Heparin Red Ultra assay to a heparin-free aqueous sample 
(red bars) and a sample containing 4,38 µg/mL heparin (blue bars), in matrices containing 20 µg/mL 
HSA and/or 25 mM TCEP (incubation time: 15 minutes). Control (leftmost bars) refers to water or 4,38 
µg/mL heparin in water, respectively.  Averages of duplicate determinations; CV averaged over all 
concentrations: 1.4 %.  
 
 
 
0,0
0,2
0,4
0,6
0,8
1,0
1,2
control TCEP 25mM HSA 20µg/mL HSA 20µg/mL
+ TCEP 25mM
N
or
m
al
is
ed
 flu
or
es
ce
nc
e
Heparin‐free sample 4,38 µg/mL heparin
 
Detection of heparin in urine 
Urine is a complex biological matrix. It is a multicomponent aqueous mixture of highly 
variable concentrations of inorganic salts, organic compounds and trace amounts of 
bioacromolecules including proteins and gylcosaminoglycans. Table 1 lists the normal 
population reference ranges of selected urine components, in comparison with their non-
interfering levels in the Heparin Red Ultra assay as shown in figure 2. The focus is on 
charged urine components that may pontentially interfere with the electroststic interaction 
between Heparin Red and heparin (compare scheme 2). 
 Compound Reference range 
for urine [23]  
Non-interfering level 
in fluorescence 
assay 
Na+ 27-167 mM 150 mM 
Mg2+ 2.5-8.5 mM 10 mM 
Ca2+ 2.5-7.5 mM 10 mM 
K+ 23-67 mM 75 mM 
Cl- 67-167 mM 150 mM 
SO42- 5-31 mM 50 mM 
HPO42- 9-28 mM 20 mM 
CS 0.5-10 µg/mL [24] 25 µg/mL 
DS n.d. [24] 25 µg/mL 
DNA < 1 µg/mL [25] 25 µg/mL 
RNA < 1 µg/mL [26] 50 µg/mL 
Glycine <3.1 mM 20 mM 
HSA 0 – 20 µg/mL ≈ 2 µg/mL* 
IgG 0 – 6 µg/mL 30 µg/mL 
 
Table 1. Selected components of urine: reference range (usually defined as the set of values 95% of 
the normal population falls within), and non-interfering concentrations of the same components with 
respect to heparin detection by Heparin Red Ultra (values taken from figure 2). “Non-interfering level” 
means that the fluorescence in the presence of these compounds is within ± 3.1 % of the control 
(compare figure 2).  * Extrapolated from figure 2. 
It is evident from table 1 that no or only little interference in the Heparin Red Ultra assay is 
expected from most of the listed urine components if present in their “normal” or reference 
 
range.  A notable exception is, however, HSA which may significantly  mask heparin 
response even at normal urinary levels (compare figure 3).  
In a preliminary evaluation, we have analysed two urine samples of healthy donors, either 
non-spiked or spiked with 4,38 µg/mL heparin (figure 5). In one sample (urine 1), spike 
recovery was similar to that in water, while in the other sample (urine 2), fluorescence 
decrease was lower than expected and, consequently, spike recovery incomplete (figure 5). 
We suspected that the masking effect of HSA was the origin of incomplete spike recovery. 
This was confirmed by quantification of HSA in the urine samples, using an antibody-based 
turbidimetric detection method (Hemocue albumin 201 system). While in urine 1, HSA was 
not detectable (< 5 µg/mL, detection limit of the method), urine 2 displayed a HSA level of 5,5 
µg/mL. The fluorescence response of the heparin–spiked urine 2 sample is in good 
agreement with that of an aqueous sample containing 5 µg/mL HSA (figure 3), supporting the 
idea that HSA partially masks the response of the assay in urine 2.   
 
Figure 5. Fluorescence response of the Heparin Red Ultra assay to heparin-free urine samples 1 and 
2 (red bars), and the same urine samples spiked with 4,38 µg/mL heparin (blue bars).  The assay with 
urine 2 was repeated after pretreatment with 25 mM TCPE (incubation time 15 minutes at ambient 
temperature). Control (leftmost bars) refers to water or 4,38 µg/mL heparin in water, respectively. 
Averages of triplicate determinations; CV averaged over all concentrations: 1.3 %. 
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HSA was further confirmed as an interfering component in urine 2 by the effect of the 
disulfide-cleaving agent TCEP. Pre-treatmrent of the sample with 25 mM TCEP for 15 
minutes results in a reduction of fluorescence response to heparin similar to the level 
observed for the control, indicating that the interference has been eliminated (compare figure 
4). Additional data with a larger number of urine samples are required to confirm the 
reliability of the Heparin Red Ultra assay combined with TCEP sample pretreatment for 
heparin quantification in urine.  
 
Conclusion 
This study addresses the need for simple and user-friendly analytical methods for the fast 
and accurate quantification of heparin in complex matrices. Commercially availbale Heparin 
Red Ultra is a ready-to-use solution that is mixed with a small volume of heparin containing 
sample in a microplate well for one minute, followed by fluorescence readout. A screening of 
typical impurities related to industrial heparin extraction from animal tissues (selected 
glycosaminoglycans, residual nucleic acids and proteins) as well as of components of the 
urine matrix (inorganic salts, amino acids, trace proteins) revealed that these compounds 
even in large excess have no or very little effect on the accuracy of heparin determination. 
Interference by human serum albumin appears to be related to extensive intramolecular 
disulfide bonding, a specific structural feature of this protein, and is readily overcome with a 
convenient sample pre-treatment protocol using the commercial disulfide cleaving agent 
tris(2-carboxyethyl)phosphine (TCEP).  A preliminary evaluation of the fluorescence assay 
for heparin detection in urine, a complex multicomponent mixture, also revealed good 
accuracy. Heparin Red Ultra may facilitate process control of raw heparin preparation and 
purification in industrial manufacturing, support quality control of heparin batches, and allow 
convenient quantification of urinary excretion in pharmacokinetic studies.   
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